Objectives: To examine the inhibitory effects of tumor necrosis factor-a on myogenic differentiation of human urethral rhabdosphincter cells.
phenylindole DM = differentiation medium FBS = fetal bovine serum GM = growth medium MAPK = mitogen-activated protein kinase MHC = myosin heavy chain PBS = phosphate-buffered saline PCR = polymerase chain reaction PI3K = phosphoinositide 3-kinase qRT-PCR = quantitative reverse transcription polymerase chain reaction RS = rhabdosphincter SUI = stress urinary incontinence SV40 Tag = Simian virus 40 T antigen TNF-a = tumor necrosis factor-a Introduction SUI is the most common type of urinary incontinence, and is defined as involuntary leakage of urine on effort, exertion, sneezing or coughing. Although there are two main pathophysiological conditions in female SUI, intrinsic sphincter deficiency, characterized by malfunction of the urethral sphincter mechanism, has been reported to be more prominent than urethral hypermobility in patients with SUI, and significantly contributes to the emergence of SUI. [1] [2] [3] In contrast, male SUI after radical prostatectomy for prostate cancer, resulting from injury to the external urethral sphincter, is occasionally intractable to treatment.
The external urethral sphincter, which is also known as the urethral RS, is a key structure of the urethral sphincter mechanism. The number of human RS cells has been noted to decrease with age as a result of apoptosis. Strasser et al. reported that age-dependent apoptosis was observed in striated muscle cells, but not in urethral smooth muscle cells, by the TUNEL assay. 4 Decreased striated muscle cell density is also noted with advancing age, concomitant with replacement by fat cells and connective tissue. 4 Thus, this decrease in the number of RS cells might be a cause of SUI in the elderly.
Meanwhile, chronic low-grade systemic inflammation is widely considered to be the underlying cause of age-related loss of muscle mass. Some groups have reported that TNF-a induces apoptosis in murine skeletal muscle cells, 5 and systemic concentrations of this inflammatory cytokine 6, 7 in the local environment of skeletal muscle increases with age. 8 Our group previously reported that TNF-a inhibited proliferation of striated muscle progenitor cells from human urethral RS. 9 Furthermore, a TNFa antagonist inhibited the effects on these cells.
However, it was difficult to continue further examining the effect of TNF-a for myogenic differentiation, because these RS progenitor cells were transfected by SV40 Tag to expand lifespan, which meant SV40 transfected cells made for only proliferation and not differentiation. 10 Therefore, we needed to establish other cell culture lines in order to continue examination for myogenic differentiation.
In the present study, we established a new cell culture system and examined the inhibitory effects of TNF-a on the myogenic differentiation of human RS progenitor cells, as we hypothesized the TNF-a might be involved in age-related decreases in the number of human RS cells and be a causative factor of SUI in the elderly population.
Methods
Primary cell culture and establishment of immortalized myogenic cells
The study protocol was reviewed and approved by the institutional review board of Oita University (Oita, Japan), and written informed consent was obtained from the patient for publication of this report.
We obtained a small external urethral sphincter specimen from a 63-year-old man with bladder cancer who underwent total cystectomy. The muscle tissue was minced and placed on 60-mm dishes in Ham's F-10 medium (Sigma, St. Louis, MO, USA) supplemented with 20% FBS (Sigma), 1% penicillin/ streptomycin (Life Technologies Corporation, Grand Island, NY, USA) and 0.05 mg/mL of bovine pituitary extract (Hammond Cell Technologies, Windsor, CA, USA). The cells were maintained in a humidified atmosphere of 5% CO 2 at 37°C.
Lentivirus transduction
Construction of lentiviral vector plasmids, CSII-CMV-CDK4R24C, CSII-CMV-cyclin D1 and CSII-CMV-TERT, which express p16-insensitive mutant of cyclin-dependent kinase 4, cyclin D1, and the catalytic subunit of telomerase, respectively, and production of VSV-G pseudotyped lentiviruses were previously described. 11 The backbone vector, CSII-CMV-RfA, was a kind gift from Dr Miyoshi (RIKEN, BRC). Primary RS progenitor cells were transduced with CSII-CMV-cyclin D1, CSII-CMV-CDK4R24C at the multiplicity of infection of 2, and CSII-CMV-TERT at the multiplicity of infection of 4, as described for immortalization of other types of human cells.
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Myogenic differentiation
Immortalized human RS cells were plated at 2 9 10 5 cells/ 60-mm dish coated with type I collagen (Corning Incorporated, Corning, NY, USA) and grown in primary cultured myocyte GM containing a high glucose concentration (4.5 g/ mL), Dubecco's modified Eagle's medium (Life Technologies Corporation) with 20% FBS (Sigma) and 2% Ultroser G serum substitute (Biosepra, Marlborough, MA, USA) under an atmosphere of 5% CO 2 at 37°C. Two days later, the medium was switched from GM to the primary cultured myocyte DM containing 2% FBS in 5 lg/mL of holo-transferrin, 10 lg/mL of insulin and 10 nmol/L selenite in high-glucose Dulbecco's Modified Eagle Medium. The human RS cells were left to differentiate to myotubes for an additional 7 days. They were treated with 1-100 ng/mL of recombinant human TNF-a (R&D Systems, Minneapolis, MN, USA) during differentiation induction. The TNF-a concentration is described in our previous study. 9 Etanercept (Pfizer, Pearl River, NY, USA) was added before TNF-a treatment. DM, TNF-a and etanercept were switched every second day.
Quantitative reverse-transcription polymerase chain reaction Total RNA was extracted using TRIzol reagent (Life Technologies Corporation, Carlsbad, CA, USA) according to the manufacturer's instructions. Total RNA (1 lg) was reverse transcribed into cDNA using the ThermoScript RT-PCR System (Life Technologies Corporation) under the following cycling conditions: denaturation at 65°C for 10 min, annealing at 55°C for 30 min and reverse transcriptase inactivation at 85°C for 5 min. Quantitative PCR was carried out using Light Cycler Master SYBRGreen I reaction mix (Roche Molecular Biochemicals, Mannheim, Germany) in triplicate on a LightCycler system (Roche Diagnostics, Indianapolis, IN, USA) for 45 cycles of amplification for each primer after 10 min of initial denaturation at 95°C. Each cycle included denaturation at 95°C for 15 s, annealing at 55°C for 5 s and polymerization at 72°C for 10 s. Specific PCR primers were to amplify MHC 1 and 2, and b-actin (Qiagen, Venlo, the Netherlands). mRNA levels were estimated according to the critical threshold value and normalized to b-actin.
Immunohistochemical staining
Myotubes of immortalized human RS cells were briefly rinsed once with ice-cold PBS (Wako Pure Chemical Industries, Osaka, Japan) and fixed with methanol for 20 min, then washed three times with PBS for 5 min each, blocked with 10% rabbit normal serum (Nichirei Biosciences, Tokyo, Japan) for 10 min and incubated with primary antibodies against CD56 (NCAM; Thermo Fisher Scientific, Waltham, MA, USA) at a dilution of 1:200, desmin (Leica Biosystem Inc., Buffalo Grove, IL, USA) at a dilution of 1:200, MHC (Merck Millipore, Darmstadt, Germany) at a dilution of 1:200 and sarcomeric actin (Dako Cytomation, Glostrup, Denmark) at a dilution of 1:50 in PBS with 1% bovine serum albumin at 4°C overnight. After washing with PBS, the cells were incubated in fluorescent isothiocyanate (Dako Cytomation) at a dilution of 1:40 in PBS with 1% bovine serum albumin for 1 h at room temperature in the dark. The cells were counterstained with DAPI (Wako Pure Chemical Industries).
Western blotting
Myotubes of immortalized human RS cells were washed once with ice-cold PBS and scraped in protein lysis buffer (50 mmol/L Tris, pH 8.0, 150 mmol/L NaCl, 0.02% NaN 3, 0.1% sodium dodecyl sulfate, 1% NP-40, 0.5% sodium deoxycholate and 1 mmol/L phenylmethylsulfonyl fluoride) with protease inhibitors. Protein concentrations were quantified by the Bradford protein assay. To detect MHC expression, equal amounts of protein (20 lg) were separated on 4-20% Tris-glycine gels (Tefco, Tokyo, Japan) and transferred to nitrocellulose membranes. After blotting, the membranes were blocked with Blocking One-P solution (Nacalai Tesque, Kyoto, Japan) for 40 min at room temperature, and incubated at 4°C overnight with MHC (Merck Millipore), phospho-p38-MAPK, total-p38-MAPK, phospho-Akt and total-Akt (Cell Signaling Technology, Inc., Danvers, MA, USA) at a dilution of 1:1000, and c-actin (Novus International, Saint Charles, MO, USA) at a dilution of 1:5000 in Can Get Signal solution 1 (Cell Signaling Technology). After washing with PBS containing 0.05% Tween, the membranes were incubated for 1 h at room temperature with secondary antibody (anti-rabbit or anti-mouse) immunoglobulin G conjugated with horseradish peroxidase at a dilution of 1:10000 in Can Get Signal solution 2. Bands were visualized using ECL Prime (Amersham Pharmacia Biotech, Little Chalfont, UK).
Statistical analysis
Statistical analysis was carried out with the Mann-Whitney test using SPSS 22.0 software (IBM-SPSS, Chicago, IL, USA).
Results
Myogenic differentiation of immortalized human RS cells
Primary human RS cells were transduced with mutant CDK4, cyclin D1 and teromerase at passage 6, as described in the Methods section. Then the cells continuously proliferated for at least 40 passages and were considered to be immortalized. As shown in Figure 1 , the immortalized human RS cells expressed markers of striated muscles, including desmin, sarcomeric actin and CD56 (NCAM). Then, the expression of MHC, which is a marker of differentiated striated muscle cells, was examined after incubation in DM. qRT-PCR showed that both MHC1 and MHC2 mRNAs were abundantly present after induction of differentiation (Fig. 2a) . Immunoblotting confirmed that MHC expression was significantly higher after differentiation induction (Fig. 2b) . Likewise, immunocytochemical analysis also showed that immortalized human RS cells differentiated into myotubes (Fig. 2c,d ).
MHC expression of differentiated immortalized human RS cells after TNF-a treatment
To examine the effect of TNF-a on the differentiation of immortalized human RS cells, we induced differentiation in DM with TNF-a at different concentrations. As shown in Figure 3a , TNF-a significantly decreased the expressions of both MHC1 and MHC2 mRNAs in a dose-dependent fashion. At the protein level, immunoblotting showed that the addition of 10 and 100 ng/mL of TNF-a significantly decreased MHC expression, as compared with control cells (Fig. 3b) . Immunocytochemical analysis also showed that TNF-a inhibited myotube formation in a dose-dependent manner ( Fig. 3c-f ).
Inhibitory effect of TNF-a inhibition with etanercept on myogenic differentiation of immortalized human RS cells
To evaluate the effect of etanercept against TNF-a-induced differential suppression, immortalized human RS cells were incubated in DM after pretreatment with 0.01-100 lg/mL of etanercept before adding 10 ng/mL of TNF-a. The addition of 1 and 100 lg/mL of etanercept significantly increased mRNA expression of both MHC1 and MHC2 in myotubes of immortalized human RS cells compared with TNF-a treatment only (Fig. 4a) . Likewise, both immunoblot and immunocytochemical analyses showed that the addition of etanercept obviously induced an increase in the expression of MHC (Fig. 4b-g ). These data showed that etanercept suppressed the inhibition of myogenic differentiation of myotubes of immortalized human RS cells after TNF-a treatment.
Signal transduction of TNF-a in myotubes of immortalized human RS cells
To gain further insight into the mechanism of etanercept, Akt and p38-MAPK protein levels were monitored by immunoblot analysis. While TNF-a treatment significantly suppressed expression of phosphorylated Akt, etanercept increased phosphorylation of Akt in a dose-dependent fashion (Fig. 5a ). In regard to the p38-MAPK phosphorylation cascade, the addition of 1 and 100 lg/mL of etanercept also suppressed the inhibition of p38 phosphorylation by TNF-a treatment in myotubes of immortalized human RS cells (Fig. 5b) . These findings showed that TNF-a suppressed myogenic differentiation of immortalized human RS cells partially through the Akt and p38-MAPK pathways.
Discussion
The results of the present study included two novel findings. First, we established an original human RS cell line. Several studies reported different proliferation and differentiation characteristics between animal myogenic cells and human myogenic cells. 13, 14 To the best of our knowledge, there have been few studies on the biology of myogenic cells differentiated from human RS cells because of the difficulty of establishing a myogenic cell lineage. In a previous study, we selectively cultured human RS progenitor cells by magnetic affinity cell sorting using an anti-neural cell adhesion molecule (NCAM) antibody, which is a cell surface marker of human muscle progenitor cells, and transfected the cells with SV40 Tag to extend the lifespan of the cells because of the weak proliferation ability and severe contamination with fibroblasts. However, the SV40 Tag might interfere with the ability of transfected cells to differentiate, while prolonging the lifespan of these cells. 15, 16 Therefore, we transduced primary culture human RS progenitor cells with cyclin-dependent kinase 4, cyclin D1 and telomerase by lentivirusmediated gene transfer to minimize the effects of transformable changes to subsequent myogenic differentiation. As a result, the immortalized human RS progenitor cells retained growth and myogenic differentiation reactivity even after long-term passage in tissue culture. Consequently, immortalized human RS progenitor cells were used for all subsequent experiments.
Second, we showed that TNF-a inhibited not only proliferation, but also myogenic differentiation of human RS cells in a dose-dependent manner. In general, muscle stem cells (i.e. satellite cells) are believed to be responsible for the development and renewal of striated muscle fibers. 17, 18 In response to stimulation by myotrauma, satellite cells become activated, proliferate and express myogenic markers. The resulting activated satellite cells (i.e. muscle progenitor cells) then fuse to existing muscle fibers or fuse together to form myotubes that ultimately differentiate into new myofibers.
Age-related changes in striated muscle in other body areas have been studied extensively. By the age of 60-70 years, overall striated muscle mass decreases by 25-30% in humans. 19 Even in RS, Strasser et al. reported that the number of RS cells in the elderly is significantly decreased as a result of apoptosis, and the amount of striated muscle fibers is decreased by replacement of striated muscle cells with fat cells and connective tissue. Chronic low-grade systemic inflammation has been proposed as a cause of age-related loss of muscle mass. TNF-a systemically increases 6, 7 in the local environment of skeletal muscle with increasing age. 8 Our previous studies showed that TNF-a induced inhibition of proliferation and apoptosis of human RS progenitor cells. The examination of myogenic differentiation in the present study found that TNF-a also inhibited myogenic differentiation of human RS progenitor cells through a part of the PI3K and p38-MAPK pathway. Furthermore, etanercept promoted differentiation of these cells by suppression of TNF-a effects.
In skeletal muscle myogenesis, activation of Akt promotes differentiation of progenitor muscle cells and maintains myoblast motility in the early phase. Even in the late phase, Akt activation is also necessary for maturation of striated muscle fibers. 20 In contrast, the activation of p38-MAPK is also essential to the differentiation and maintenance of myoblasts by positively regulating myogenesis through MyoD and myocyte enhancer factor 2 proteins in the early phase. In the terminal differentiation phase, p38-MAPK-induced activation of muscle regulatory factor 4 affects differentiation of myoblasts into myotubes. 21, 22 In addition, some studies reported crosstalk between p38-MAPK and Akt during myogenic differentiation. 23, 24 However, further investigations into cell signaling of myogenic differentiation in human RS are required, as this could possibly be a unique characteristic considering its origin. 25 There were several limitations to the present study. First, only one male RS specimen was used in this study, because we were unable to obtain RS samples from other patients, including women, who underwent total cystectomy, and there were few viable RS cells in the obtained sample as a result of thermal denaturation by electrosurgical manipulation. In women, it is also difficult to obtain viable RS cells from few cases. Although many studies reported that the anatomy of the lower urinary tract is different between human males and females in structure and function, little is known about the sex difference of RS cells themselves. Therefore, we require future study involving more patients, including women. Additionally, future translational research is also required, as the present study only included an in vitro analysis.
At present, there is no useful pharmacological therapy for SUI, thus surgical intervention, such as implantation of a mesh sling or artificial sphincter, is typically carried out. However, xenogeneic transplantation is invasive. Recent breakthroughs in the regeneration of human RS cells shows that it seems to be a promising new therapy for SUI, and can be achieved by autologous transplantation of muscle-or adipose-derived stem cells. 26, 27 As a mechanism of tissue regeneration, various cytokines and growth factors have been investigated. 28 Likewise, inflammatory cytokines, including TNF-a, might also affect the regenerative mechanism of human RS cells.
In conclusion, TNF-a might be involved in age-related decreases in the number of human urethral RS cells and be a causative factor of SUI in the elderly. Furthermore, inhibition of TNF-a could be a useful target in the development of novel strategies for stimulation of RS cell regeneration to treat SUI.
